# Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

> **NCT04007835** · NA · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 120 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT04007835
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07
- **Primary completion:** 2021-07
- **Final completion:** 2021-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007835, "Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04007835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*